Gemcitabine and cisplatin (GC) for metastatic breast cancer (BC).

871 Background: Metastasic BC has a poor prognosis, chemotherapy is the main treatment; anthracyclines and taxanes are considered as first line of treatment. New antitumor agents and combinations are explored. GC has shown to be effective in metastasic BC.,To evaluate efficacy and safety of GC in metastasic BC pts.,> 20 yrs old with confirmed diagnosis of metastasic BC, Karnofsky scale > 60, medullar, hepatic and renal normal function. G 1250 mg/m2 d1,8 and C 35 mg/m2 d1,8 or 70 mg/mg d1. Age, previous therapy, number and sites of metastasis, cycles, therapeutic response and duration, as well as hematologic and non-hematologic toxicity were analized.,19 women, mean age 51.4 +/- 10.6 yrs old, range 37 - 71. All in metastasic phase, metastasis to liver in 10 pts, lung 12, bone 9, cervical lymph nodes 4, brain 2, skin 3 pt. GC as first line in 2 pt, as second in 6, as third in 9, as fourth and fifth in 1pt. Seventeen pts had received anthracyclines and taxanes. Mean cycles of GC 5.2, range 1 to 9. CR 2 pt, PR 6, SD 8, Progression in 2 and one non evaluable; OR: 44.4% and clinical benefit 84.2%. Mean duration response 6.8 +/- 3.7 mos, range 2 to 15. Mean TTPd 7.9 +/- 4.0 mos, range: 2 - 20. Twelve deaths has been registered (63.1%). Mean survival: 9.7 +/- 4.2 mos, range 2 - 20. Hematologic toxicity: anemia GI 75%; leucopenia GI 37.5%, GII 6.25%; neutropenia GI 12.5%, GII 25%; thrombocytopenia GI 56.2%. Non hematologic toxicity: nausea GII 25%, asthenia GI 6.2%, vomiting GI 6.2%.,GC is very active in pretreated metastasic BC, it is associated to toxicity of low intensity. New designs for trials in phase III for evaluating GC as first line treatment are required. No significant financial relationships to disclose.